
Matchpoint Therapeutics
Matchpoint: A biotech firm innovating precision covalent medicines for immune diseases via ACE platform.

Matchpoint: A biotech firm innovating precision covalent medicines for immune diseases via ACE platform.
Matchpoint Therapeutics, founded with the mission to revolutionize the treatment of immune diseases and other serious illnesses, focuses on the development of precision covalent medicines. Utilizing their proprietary Advanced Covalent Exploration (ACE) platform, Matchpoint integrates advanced chemoproteomics and machine learning to discover and develop innovative therapies. The company's primary market focus is on immune system diseases, leveraging their expertise to create targeted and effective treatments.
Notable investors in Matchpoint Therapeutics include Sanofi, which has backed the company with a $100 million investment. This significant funding underscores the confidence in Matchpoint's potential to impact the biotechnology sector. Key achievements include the successful launch of their ACE platform and securing substantial financial support to advance their research and development efforts. Matchpoint's innovative approach has positioned it as a promising player in the biotech industry, with the potential to make a significant impact on the treatment of immune diseases.
Companies similar to Matchpoint Therapeutics include Metaphore Biotechnologies, Faze Medicines, Frontier Medicines and Ampersand Biomedicines.
Matchpoint Therapeutics was founded in 2021.
Matchpoint Therapeutics' headquarters is located in Cambridge, MA, US.
Matchpoint Therapeutics' most recent funding round was for $150M (USD) in October 2026.
As of Oct 7, 2026, Matchpoint Therapeutics has disclosed funding of $250M (USD). Undisclosed round amounts are excluded.
Matchpoint Therapeutics has 28 employees as of Feb 5, 2024.

Ampersand Biomedicines
ampersand.bio